Everything below concerns thymalfasin. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-08-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
Thymosin alpha 1 is a 28-amino-acid peptide first isolated from thymosin fraction 5, a bovine thymic extract. Its sequence begins with an acetylated serine residue and carries a high proportion of acidic residues, so the molecule has a net negative charge near neutral pH. Despite the shared name, it is unrelated in sequence to the thymosin beta family. Synthetic material prepared by solid-phase peptide synthesis is identical in sequence to the natural peptide.
Several names appear in the literature for this peptide, including thymalfasin and the abbreviation T-alpha-1. Naming conventions differ among research articles, regulatory documents, and supplier catalogs, which complicates literature searches. Both synthetic and recombinant production routes yield a peptide with the same 28-residue sequence as the thymic isolate. Because the thymosin label also covers unrelated peptides, sources should be compared by sequence rather than by name alone.
The peptide occurs naturally in thymic tissue and has been detected in serum and other biological fluids. Reported concentrations are low, and reliable measurement generally requires immunoassay or mass spectrometry with an enrichment step. It is released from a larger precursor, prothymosin alpha, by proteolytic cleavage, although the enzymes involved are not fully characterized. Whether circulating levels reflect thymic output specifically remains an open question.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C129H215N33O55 | Calculated for the acetylated 28-residue peptide |
| Appearance | White to off-white powder | Lyophilized solid recovered from aqueous buffer |
| Solubility | Freely soluble in water | Typically dissolved in water or buffer before use |
| Typical storage | -20 C or below, desiccated | Protect from light and avoid repeated freeze-thaw cycles |
| Identity testing | Reverse-phase HPLC with mass spectrometry | Retention time and measured mass confirm the sequence |
The lyophilized peptide is generally stable for extended periods when kept cold and dry. Once dissolved, aqueous solutions are less stable; hydrolysis, oxidation, and aggregation can degrade the material. Storage at -20 °C or lower slows these processes. Repeated freeze-thaw cycles are best avoided because they can promote aggregation. The exact shelf life depends on formulation, pH, and concentration, so stability studies are typically performed for each specific product.
Quality control for thymosin alpha-1 focuses on identity, purity, and potency. Identity is confirmed by mass spectrometry and amino acid analysis, while purity is assessed by chromatography with limits on related substances and residual solvents. Potency assays may use cell-based immune readouts, but these are not standardized across laboratories. Regulatory status differs by jurisdiction; no product is approved in the United States for clinical use, whereas some other countries register injectable forms for specific indications.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Long-term storage is generally at minus twenty degrees Celsius or colder, preferably desiccated and protected from light. Lyophilized material is more stable than reconstituted solution, which degrades faster at room temperature. Stability depends on pH, ionic strength, and the presence of oxidising agents. Published stability data for the peptide are limited, so storage claims in catalogues should be treated as general guidance rather than measured guarantees. Freeze-thaw cycles are kept to a minimum.
Identity and purity are normally confirmed by reversed-phase high-performance liquid chromatography and mass spectrometry. The expected mass for the acetylated 28-residue peptide is close to 3108 daltons, and a mass shift indicates a modification or truncation. Peptide mapping after enzymatic digestion can resolve sequence-level questions. Counter-ion content, water content, and residual solvents are separate quality attributes that a certificate of analysis may or may not report. Aggregation is monitored by size-exclusion chromatography when relevant.
===== Mechanism ===== A sequential mechanism has been proposed for PurT GAR transformylase in which a short lived formyl phosphate intermediate is proposed to first form. This formyl phosphate intermediate then undergoes nucleophilic attack by the GAR amine for transfer of the formyl group. A formyl phosphate intermediate has been detected in mutagenesis experiments, in which the mutant PurT GAR transformylase had a weak affinity for formate. Incubating PurT GAR transformylase with formyl phosphate, ADP, and GAR, yields both ATP and FGAR. This further indicating that formyl phosphate may be an intermediate, as it is kinetically and chemically competent to carry out the formylation reaction in the enzyme. An enzyme phosphate intermediate preceding the formylphosphate intermediate has also been proposed to form based on positional isotope exchange studies. However, structural data indicates that the formate may be positioned for a direct attack on the γ-phosphate of ATP in the enzyme's active site to form the formylphosphate intermediate.
As a result, they were unable to receive the first payments from the Auxílio Reconstrução fund, valued at $5.1 million real. In June, fears of floods began to worry the people of Porto Alegre, causing thousands to abandon their homes. Porto Alegre only was able to have the "pump houses" - buildings that housed the electric tools necessary to drain floods in the city - functioning again by the start of July.
==== Absorption ==== The absolute bioavailability of gepirone is 14 to 17%. The time to peak concentrations of gepirone with the extended-release formulation is 6 hours. When taken with a high-fat meal, the time to peak levels decreases to 3 hours. A high-fat meal increases exposure to gepirone, with the effect increasing dependent on the amount of fat in the meal. Peak concentrations were increased by 27% with a low-fat meal, 55% with a medium-fat meal, and 62% with a high-fat meal, while area-under-the-curve levels of gepirone were increased by 14% with a low-fat meal, 22% with a medium-fat meal, and 32 to 37% with a high-fat meal. The effect was similar for the metabolites of gepirone, 1-PP and 3'-hydroxygepirone (3'-OH-gepirone).
Sources: en.wikipedia.org
This led to endemic pellagra in poor populations throughout the southern US in the early 20th century. A more varied diet and fortification of wheat flour, the other staple food, have essentially eliminated this deficiency. Although maize cultivation spread far beyond the Americas via colonialism, the process of nixtamalization did not. For this reason, outbreaks of pellagra occurred in many areas of Europe, where corn often became a staple crop due to its high caloric efficiency relative to the land use required for its cultivation. A prominent example of endemic pellagra occurred in northern Italy in the late 19th century, from which the English term pellagra derives: "pel" meaning skin and "agra" meaning rough or sour in the Bergamo dialect.
The energy levels of a single particle in a quantum dot can be predicted using the particle in a box model in which the energies of states depend on the length of the box. For an exciton inside a quantum dot, there is also the Coulomb interaction between the negatively charged electron and the positively charged hole. By comparing the quantum dot's size to the exciton Bohr radius, three regimes can be defined. In the 'strong confinement regime', the quantum dot's radius is much smaller than the exciton Bohr radius, respectively the confinement energy dominates over the Coulomb interaction. In the 'weak confinement' regime, the quantum dot is larger than the exciton Bohr radius, respectively the confinement energy is smaller than the Coulomb interactions between electron and hole. The regime where the exciton Bohr radius and confinement potential are comparable is called the 'intermediate confinement regime'.
== Function == The adiponectin receptors, AdipoR1 and AdipoR2, serve as receptors for globular and full-length adiponectin and mediate increased AMPK and PPAR-α ligand activities, as well as fatty acid oxidation and glucose uptake by adiponectin. In 2016, the University of Tokyo announced that it would launch an investigation into claims of fabrication of AdipoR1 and AdipoR2 identification data, as accused by an anonymous person/group called Ordinary researchers.
== Books == The Malay Dilemma (1970) ISBN 981-204-355-1 The Challenge (1986) ISBN 967-978-091-0 Regionalism, Globalism, and Spheres of Influence: ASEAN and the Challenge of Change into the 21st century (1989) ISBN 981-303-549-8 Mahathir, Great Malaysian Hero (1990) ISBN 983-9683-00-4 The Asia That Can Say No (1994) ISBN 433-405-217-7 The Pacific Rim in the 21st century (1995) The Challenges of Turmoil (1998) ISBN 967-978-652-8 The Way Forward (1998) ISBN 0-297-84229-3 A New Deal for Asia (1999) Islam & The Muslim Ummah (2001) ISBN 967-978-738-9 Globalisation and the New Realities (2002) Reflections on Asia (2002) ISBN 967-978-813-X The Malaysian Currency Crisis: How and why it Happened (2003) ISBN 967-978-756-7 Mahathir: 22 Years, 22 Voices (2003) Dr Mahathir Mohamad - Father of Sports Development (2003) Achieving True Globalisation (2004) ISBN 967-978-904-7 Islam, Knowledge, and Other Affairs (2006) ISBN 983-3698-03-4 Principles of Public Administration: An Introduction (2007) ISBN 978-983-195-253-5 Chedet.com Blog Merentasi Halangan (Bilingual) (2008) ISBN 967-969-589-1 A Doctor in the House: The Memoirs of Tun Dr Mahathir Mohamad (2011) ISBN 9789675997228 Doktor Umum: Memoir Tun Dr. Mahathir Mohamad (2012) ISBN 9789674150259 Blogging to Unblock (Book 2): A Citizen's Rights (2013) ISBN 9789679696288 Dr. M: Apa Habaq Orang Muda? (2016) ISBN 9789671367995 Capturing Hope: The Struggle Continues for a New Malaysia (2021) ISBN 9789672923183 A Conversation with Tun Dr Mahathir bin Mohamad: A Legacy of Leadership and Vision (2025) ISBN 9789670821436
Sources: en.wikipedia.org
It is a 28-amino-acid peptide originally purified from a bovine thymic extract and later produced synthetically. It is studied mainly for its effects on immune cell function.
No. The two peptides share part of a name but differ in length, sequence, and net charge. Literature searches that treat them as one compound return misleading results.
Solid-phase peptide synthesis is the usual route, and recombinant expression has also been described. Both approaches produce material matching the natural sequence.
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.